BIOMAT Database Logo BIOMAT Database Logo

[Behavior of urinary excretion of cyclic AMP in post-menopausal osteoporosis during therapy with salmon calcitonin]. 1982

R Nuti, and M Galli, and G A Righi, and V Turchetti, and M S Campagna, and B Franci

Salmon calcitonin has been administered at a dose of 100 U.M.R.C. for 6 months in 10 patients suffering from post-menopausal osteoporosis. During treatment, calcium plasma levels fluctuated but tended to fall, while urinary excretion of cyclic AMP rose, this pointing to an enhancement of parathyroid function. After 6 months an increase in intestinal calcium absorption and a decrease in bone turnover were also observed, the bone mineral content evaluated by bone densitometry showed a slight quantitative increase but proved to be substantially unchanged. Salmon calcitonin thus proved capable of interfering with bone turnover by reducing the bone resorption. By fostering an increase in parathyroid hormone production, it also made it possible to exploit that anabolic effect which, in low doses, the parathormone exerts on the bone tissue.

UI MeSH Term Description Entries
D007408 Intestinal Absorption Uptake of substances through the lining of the INTESTINES. Absorption, Intestinal
D008593 Menopause The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age. Change of Life, Female
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010024 Osteoporosis Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis. Age-Related Osteoporosis,Bone Loss, Age-Related,Osteoporosis, Age-Related,Osteoporosis, Post-Traumatic,Osteoporosis, Senile,Senile Osteoporosis,Osteoporosis, Involutional,Age Related Osteoporosis,Age-Related Bone Loss,Age-Related Bone Losses,Age-Related Osteoporoses,Bone Loss, Age Related,Bone Losses, Age-Related,Osteoporoses,Osteoporoses, Age-Related,Osteoporoses, Senile,Osteoporosis, Age Related,Osteoporosis, Post Traumatic,Post-Traumatic Osteoporoses,Post-Traumatic Osteoporosis,Senile Osteoporoses
D001862 Bone Resorption Bone loss due to osteoclastic activity. Bone Loss, Osteoclastic,Osteoclastic Bone Loss,Bone Losses, Osteoclastic,Bone Resorptions,Loss, Osteoclastic Bone,Losses, Osteoclastic Bone,Osteoclastic Bone Losses,Resorption, Bone,Resorptions, Bone
D002116 Calcitonin A peptide hormone that lowers calcium concentration in the blood. In humans, it is released by thyroid cells and acts to decrease the formation and absorptive activity of osteoclasts. Its role in regulating plasma calcium is much greater in children and in certain diseases than in normal adults. Thyrocalcitonin,Calcitonin(1-32),Calcitrin,Ciba 47175-BA,Eel Calcitonin,Calcitonin, Eel,Ciba 47175 BA,Ciba 47175BA
D002118 Calcium A basic element found in nearly all tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes. Coagulation Factor IV,Factor IV,Blood Coagulation Factor IV,Calcium-40,Calcium 40,Factor IV, Coagulation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000242 Cyclic AMP An adenine nucleotide containing one phosphate group which is esterified to both the 3'- and 5'-positions of the sugar moiety. It is a second messenger and a key intracellular regulator, functioning as a mediator of activity for a number of hormones, including epinephrine, glucagon, and ACTH. Adenosine Cyclic 3',5'-Monophosphate,Adenosine Cyclic 3,5 Monophosphate,Adenosine Cyclic Monophosphate,Adenosine Cyclic-3',5'-Monophosphate,Cyclic AMP, (R)-Isomer,Cyclic AMP, Disodium Salt,Cyclic AMP, Monoammonium Salt,Cyclic AMP, Monopotassium Salt,Cyclic AMP, Monosodium Salt,Cyclic AMP, Sodium Salt,3',5'-Monophosphate, Adenosine Cyclic,AMP, Cyclic,Adenosine Cyclic 3',5' Monophosphate,Cyclic 3',5'-Monophosphate, Adenosine,Cyclic Monophosphate, Adenosine,Cyclic-3',5'-Monophosphate, Adenosine,Monophosphate, Adenosine Cyclic

Related Publications

R Nuti, and M Galli, and G A Righi, and V Turchetti, and M S Campagna, and B Franci
[Metabolic changes induced with salmon calcitonin in post-menopausal osteoporosis].
September 1980, Minerva medica,
R Nuti, and M Galli, and G A Righi, and V Turchetti, and M S Campagna, and B Franci
[Long-term local tolerability to intranasally administered salmon calcitonin in post-menopausal osteoporosis].
December 1992, Minerva medica,
R Nuti, and M Galli, and G A Righi, and V Turchetti, and M S Campagna, and B Franci
[Rheologic effects of salmon calcitonin on post-menopausal osteoporosis. Results of a preliminary study].
January 1991, Minerva medica,
R Nuti, and M Galli, and G A Righi, and V Turchetti, and M S Campagna, and B Franci
Abnormal urinary sediment during therapy with synthetic salmon calcitonin.
September 1971, The Journal of clinical endocrinology and metabolism,
R Nuti, and M Galli, and G A Righi, and V Turchetti, and M S Campagna, and B Franci
Treatment of post-menopausal osteoporosis with recombinant human growth hormone and salmon calcitonin: a placebo controlled study.
January 1997, Clinical endocrinology,
R Nuti, and M Galli, and G A Righi, and V Turchetti, and M S Campagna, and B Franci
[Proceedings: Urinary excretion of cyclic AMP during expansion in rats].
September 1975, Journal d'urologie et de nephrologie,
R Nuti, and M Galli, and G A Righi, and V Turchetti, and M S Campagna, and B Franci
Treatment of post-menopausal osteoporosis with phosphate and intermittent calcitonin.
January 1986, International journal of clinical pharmacology research,
R Nuti, and M Galli, and G A Righi, and V Turchetti, and M S Campagna, and B Franci
Urinary cyclic AMP excretion during volume expansion in the rat.
June 1977, Canadian journal of physiology and pharmacology,
R Nuti, and M Galli, and G A Righi, and V Turchetti, and M S Campagna, and B Franci
Urinary excretion of cyclic AMP in hyperparathyroidism.
January 1978, Scandinavian journal of urology and nephrology,
R Nuti, and M Galli, and G A Righi, and V Turchetti, and M S Campagna, and B Franci
Analgesic effect of intranasal and intramuscular salmon calcitonin in post-menopausal osteoporosis: a double-blind, double-placebo study.
December 1994, Aging (Milan, Italy),
Copied contents to your clipboard!